New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Avadel Pharmaceuticals plc

Contributing Author

Recent Articles by Avadel Pharmaceuticals plc

Sep-16	Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding AVDL GlobeNewswire
Sep-10	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) AVDL GlobeNewswire
Sep-05	Avadel Pharmaceuticals to Present New Data on LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 AVDL GlobeNewswire
Sep-03	Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd AVDL GlobeNewswire
Aug-29	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences AVDL GlobeNewswire
Aug-07	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) AVDL GlobeNewswire
Aug-07	Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance AVDL GlobeNewswire
Jul-31	Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 AVDL GlobeNewswire
Jul-21	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) AVDL GlobeNewswire
Jun-30	Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation AVDL GlobeNewswire
Jun-16	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) AVDL GlobeNewswire
Jun-05	Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia AVDL GlobeNewswire
May-29	Avadel Pharmaceuticals to Present New Data on LUMRYZ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 AVDL GlobeNewswire
May-29	Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference AVDL GlobeNewswire
May-13	Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer AVDL GlobeNewswire
May-13	Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference AVDL GlobeNewswire
May-08	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) AVDL GlobeNewswire
May-07	Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance AVDL GlobeNewswire
May-06	Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction AVDL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.